ARITEP: Serotonin Control of Impulsivity in Tourette Disorder

Sponsor

Hospices Civils de Lyon (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05942716

Collaborator

(none)

Enrollment

Locations

Arm

Anticipated Duration (Months)

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Tourette disorder (TD) is a neurodevelopmental disorder characterized by motor and vocal tics. It is often associated with multiple psychiatric comorbidities involving a high degree of impulsivity such as obsessive-compulsive disorders (OCD), attention-deficit hyperactivity disorders (ADHD), and intermittent explosive disorders (IED). Although a substantial body of clinical studies have emphasized the role of the dopamine system in motor symptoms, little is known about how the serotonergic (5-HT) system modulate both cognitive and affective abilities in TD. Several lines of evidence suggest that different 5-HT receptor subtypes may constitute a crucial factor in the development and maintenance of different symptoms. Because abnormal 5-HT2A receptor bindings have been reported in patients with TD and aripiprazole (drug of first choice) is a 5-HT2A antagonist, we hypothesize that 5-HT2A receptors may play an important role in regulating psychiatric symptoms in TD such as those characterized by impulsive behaviors. To investigate the involvement of 5-HT2A receptors in TD, we propose to perform a multimodal imaging study with 20 adult patients (ON and OFF treatment). Neuroimaging data will be collected with a hybrid system that simultaneously combines the positron emission tomography (PET) and the functional magnetic resonance imaging (fMRI). A highly selective PET radiotracer ([18F]-altanserin) will map 5-HT2A receptor bindings in the whole brain, while fMRI will provide detail information regarding the altered brain activities.

Condition or Disease	Intervention/Treatment	Phase
Tourette Disorder	Drug: Administration of a PET radiotracer	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

20 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Involvement of the Serotonergic System in the Control of Impulsivity in Tourette Disorder.

Anticipated Study Start Date :

Sep 1, 2023

Anticipated Primary Completion Date :

Sep 1, 2026

Anticipated Study Completion Date :

Sep 1, 2027

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Tourette disorder 20 mixt adult patients with TD. Patients will be recruited if a current treatment by aripiprazole (5-15 mg) is already scheduled before the study.	Drug: Administration of a PET radiotracer A highly selective 5-HT2A receptor ligand ([18F]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine. Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic.

Arm

Intervention/Treatment

Experimental: Tourette disorder

20 mixt adult patients with TD. Patients will be recruited if a current treatment by aripiprazole (5-15 mg) is already scheduled before the study.

Drug: Administration of a PET radiotracer

A highly selective 5-HT2A receptor ligand ([18F]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine. Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic.

Outcome Measures

Primary Outcome Measures

Correlation coefficients between receptor-specific imaging data (PET) and scores of impulsivity measured by the Barratt scale (BIS11). [As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.]
Correlation coefficients between changes in the binding potential (BPND) of [18F]-altanserin measured voxel-by-voxel in the whole brain and the evolution of scores BIS11 in TD patients.

Secondary Outcome Measures

Correlation coefficients between receptor-specific imaging data (PET) and other clinical/behavioral scores. [As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.]
Correlation coefficients between changes in the binding potential (BPND) of [18F]-altanserin measured voxel-by-voxel in the whole brain and the evolution of other clinical scores and task performance of TD patients.
Correlation coefficients between functional imaging data (fMRI) and scores of impulsivity measured by the Barratt scale (BIS11). [As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.]
Correlation coefficients between changes in the BOLD signal measured voxel-by-voxel in the whole brain and the evolution of scores BIS11 in TD patients.
Correlation coefficients between functional imaging data (fMRI) and other clinical/behavioral scores. [As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.]
Correlation coefficients between changes in the BOLD signal measured voxel-by-voxel in the whole brain and the evolution of other clinical scores and task performance of TD patients.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria * :
Male or Female
Diagnosed with a Tourette Disorder following the DSM-5
Age between 18-65 years
Member of a social security scheme in France
Freely-given informed consent to participate to this study (written form)
With a current treatment by aripiprazole already scheduled
With Tics compatible with TEP/fMRI exams
Having (for women only) effective contraception throughout participation in the study.

Exclusion Criteria * :

Male or Female
A serious not controlled psychiatric comorbidity
A serious, evolving or debilitating pathology with a potential influence on the study
Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin)
Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia)
Women breastfeeding
Protected or restricted person (administratively or in judicial terms)
Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study
Do not speak french

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Service de neurologie C Hôpital neurologique Pierre Wertheimer/GHE Hospices Civils de Lyon	Bron		France	69677
2	Centre de Référence Syndrome Gilles de la Tourette Département de Neurologie Pôle des Maladies du Système Nerveux Hôpital de la Pitié-Salpêtrière	Paris		France	75013